Literature DB >> 10613658

Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.

B N Bouma1, L O Mosnier, J C Meijers, J H Griffin.   

Abstract

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) also known as plasma procarboxypeptidase B is activated by relatively high concentrations of thrombin in a reaction stimulated by thrombomodulin. In plasma an intact factor XI-dependent feed back loop via the intrinsic pathway is necessary to generate sufficient thrombin for TAFI activation. This thrombin generation takes place after clot formation with consequent down-regulation of fibrinolysis. We developed a specific and sensitive assay for activated TAFI (TAFIa) and studied its factor XI-dependent generation during clot formation. In the absence of thrombomodulin, addition of 20 nM thrombin to normal plasma generated 5-10% of the amount of TAFIa generated by 20 nM thrombin in the presence of 8 nM thrombomodulin. Minimal activation of TAFI was detected in factor II deficient plasma when clotting was initiated by 20 nM thrombin. Addition of 320-640 nM of thrombin to factor II deficient plasma resulted in the same amount of TAFIa as in normal plasma, suggesting that approximately 50% of factor II has to be converted to thrombin for extensive activation of TAFI. A Mab that neutralizes activated factor XII had no effect on TAFI activation indicating that an intact contact system is not necessary for the activation of TAFI. The dependency of TAFI activation of factor XI was tested using a Mab that neutralizes activated factor XI. When plasmas from 13 healthy individuals were tested, this Mab reduced TAFI activation by 65% (range 35-89%). Our results indicate that activation of TAFI in serum after clot formation can be quantitated and that it takes place in both factor XI-dependent and factor XI-independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613658

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

2.  Successful perioperative management in a patient with factor XI deficiency.

Authors:  Margaret L McCarthy; Sarah M Ordway; Ryan M Jones; Jeremy G Perkins
Journal:  BMJ Case Rep       Date:  2018-02-21

Review 3.  The many faces of the contact pathway and their role in thrombosis.

Authors:  Rebecca S Woodruff; Bruce Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

4.  Feedback activation of factor XI by thrombin does not occur in plasma.

Authors:  Donna L Pedicord; Dietmar Seiffert; Yuval Blat
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-25       Impact factor: 11.205

5.  Discordant fibrin formation in hemophilia.

Authors:  K E Brummel-Ziedins; R F Branda; S Butenas; K G Mann
Journal:  J Thromb Haemost       Date:  2009-01-28       Impact factor: 5.824

6.  Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD.

Authors:  Michael Walsh; Claudette Bethune; Andrew Smyth; Jessica Tyrwhitt; Shiangtung W Jung; Rosie Z Yu; Yanfeng Wang; Richard S Geary; Jeffrey Weitz; Sanjay Bhanot
Journal:  Kidney Int Rep       Date:  2021-11-24

Review 7.  Chemerin Forms: Their Generation and Activity.

Authors:  Lei Zhao; Lawrence L Leung; John Morser
Journal:  Biomedicines       Date:  2022-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.